CELU Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Celularity Inc (CELU) does not currently present a strong buy opportunity for a beginner, long-term investor with $50,000-$100,000 available. The stock's financial performance is weak, with declining revenue and gross margin, and the technical indicators are neutral. Additionally, there are no strong proprietary trading signals or significant positive catalysts to justify immediate action.
The MACD is slightly positive but contracting, RSI is neutral at 50.544, and moving averages are converging, indicating no clear trend. Support and resistance levels suggest limited immediate upside potential.
Celularity entered a strategic partnership that could provide up to $35 million in payments while retaining exclusive manufacturing rights for its biomaterials.
Revenue dropped significantly by -43.16% YoY in Q3 2025, and gross margin declined sharply by -64.94% YoY. Additionally, the stock has a low chance of significant price appreciation in the short term based on historical patterns.
In Q3 2025, revenue decreased to $5.28 million (-43.16% YoY), gross margin dropped to 19% (-64.94% YoY), and net income improved slightly to -$23.08 million (+43.35% YoY). EPS improved to -0.88 (+20.55% YoY), but overall financial performance remains weak.
No recent analyst rating or price target changes available for CELU.
